BRIEF — Boehringer steps up contract manufacturing at China facility

Privately-held German pharma major Boehringer Ingelheim has unveiled new technology to enhance its contract manufacturing offering in China.

The company’s contract manufacturing business, named Boehringer Ingelheim BioXcellence, has a new filling line at a commercial manufacturing facility in Shanghai that was officially put into operation in May 2017.

This means that the facility now offers manufacturing of drug substance and drug product all under one roof.

Boehringer, which also has production facilities in Germany, Austria and the USA, hopes to become China’s first international provider of biopharmaceutical contract manufacturing solutions with all-round services.